PCSK9 and acute coronary syndrome: Early initiation of PCSK9 inhibitors, defined as administration during hospitalization or within four weeks following the onset of acute coronary syndrome (ACS), has been demonstrated to rapidly and significantly reduce levels of low-density lipoprotein cholesterol (LDL-C), triglycerides, and non-high-density lipoprotein cholesterol.